Successful Clinical Trials, Data Presentations, Promising Studies, Fulfilled Agreements and Investors Conferences - Research Report on Arena, BioMarin, Clovis Oncology, MannKind, and Medivation

News provided by

Sep 03, 2013, 08:00 ET

NEW YORK, September 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Clovis Oncology, Inc. (NYSE: CLVS), MannKind Corp. (NASDAQ: MNKD), and Medivation, Inc. (NASDAQ: MDVN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Arena Pharmaceuticals, Inc. Research Report

On August 28, 2013, Arena Pharmaceuticals, Inc. (Arena) announced that a Phase 1b clinical trial for APD811 - an investigational oral prostacyclin (IP) receptor agonist created for the treatment of pulmonary arterial hypertension (PAH) has been successfully completed. Arena informed that it plans to begin a Phase 2 clinical trial for APD811 in Q1 2014. William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer, commented, "Arena's internal GPCR-focused efforts led to the discovery of this novel drug candidate. We believe APD811 is a promising new chemical entity that could improve current patient care by providing an oral option for IP-targeted therapy. Based on the encouraging Phase 1 results, we look forward to initiating the Phase 2 program early next year." According to the Company, this Phase 1b clinical trial evaluated the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/6a95_ARNA]

BioMarin Pharmaceutical Inc. Research Report

On August 16, 2013, BioMarin Pharmaceutical Inc. (BioMarin) reported that its abstract, PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2 was chosen as a late breaking abstract by the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress in Amsterdam, The Netherlands. The Company stated that it will present the latest data from its ongoing Phase 1/2 trial for genetically-defined cancers. BioMarin informed that the data will be featured in an oral presentation to be held on September 29, 2013 at the European Cancer Congress Data Presentation at 10:45 a.m. Hank Fuchs, M.D., Chief Medical Officer of BioMarin, commented, "We are delighted that the European Cancer Congress has included an update to our BMN 673 data on our Phase 1/2 program as a late-breaking abstract at this important medical meeting. We are on track to initiate a Phase 3 program in germline BRCA mutation metastatic breast cancer by the end of September and continue to see potential for BMN 673 to be the best-in-class PARP inhibitor." The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9b6c_BMRN]

Clovis Oncology, Inc. Research Report

On August 28, 2013, Clovis Oncology, Inc. (Clovis Oncology) reported that it has successfully given dose of its new hydrobromide salt tablet formulation of CO-1686 to the first patient under its ongoing Phase I dose-finding portion of its Phase I/II clinical study. Patrick Mahaffy, President and CEO of Clovis Oncology, commented, "We believe this is a very important step in the development of CO-1686, given the improved pharmaceutical qualities of the hydrobromide salt formulation. Over the next several months we will transition all current patients on the original capsule form of CO-1686 to this new formulation, and, of course, continue to enroll new patients as well." The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/6a2a_CLVS]

MannKind Corp. Research Report

On August 16, 2013, MannKind Corp. (MannKind) reported that in accordance with a Facility Agreement dated July 1, 2013 between Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively known as Deerfield) and the Company, the conditions that obligated Deerfield to purchase the second $40 million tranche of 9.75% senior secured convertible notes (the Convertible Notes) have now been accomplished. According to the Company, the second tranche of the Convertible Notes was subject to the achievement of Phase 3 data from studies 171 and 175 that met the primary efficacy endpoints of these studies. MannKind informed that the Facility Agreement states that Deerfield must purchase at least four equal tranches of Convertible Notes for total gross proceeds of up to $160 million. The Company also stated that the closing of the second tranche is slated to happen on or before September 6, 2013. The Full Research Report on MannKind Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/044e_MNKD]

Medivation, Inc. Research Report

On August 27, 2013, Medivation, Inc. (Medivation) announced that it will participate at the Morgan Stanley Global Healthcare Conference on September 10, 2013, 1:30 p.m. ET at the Grand Hyatt in New York, NY. The Company informed that David Hung, M.D., President and CEO, will speak at the event. According to Medivation, interested parties can access the live audio webcast via the Company website and a replay of the webcast will also be available on the Company's website for 30 days post the event. The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4277_MDVN]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner